Deltex Medical Group plc provided revenue guidance for the second half of 2022. The Board's expectation for the second half of 2022 is that the number of elective procedures in the UK and USA will increase and access into hospitals will improve for teams of clinical educators and sales experts. This, along with the anticipated European launch of next generation TrueVue monitor, which includes a novel non-invasive modality, later this year is expected to drive higher revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 GBX | 0.00% | 0.00% | -20.69% |
May. 08 | TRADING UPDATES: ECO hails vaccine results; Plant Health sales down | AN |
Apr. 02 | EARNINGS: AdvancedAdvT hails "good progress" after Capita deal | AN |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.69% | 2.78M | |
+4.27% | 191M | |
-20.00% | 78.31M |
- Stock Market
- Equities
- DEMG Stock
- News Deltex Medical Group plc
- Deltex Medical Group plc Provides Revenue Guidance for the Second Half of 2022